Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 2, 1997, Pages 435-439

  Klepser, Michael E ^a,b,d   Marangos, Markos N ^a   Zhu, Zhu ^a   Nicolau, David P ^a,b   Quintiliani, Richard ^a,c   Nightingale, Charles H ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BACTEROIDES FRAGILIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SERUM BACTERICIDAL ACTIVITY;

EID: 0031054655     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.2.435     Document Type: Article

References (17)

1. Akova, J., Y. Yang, and D. M. Livermore. 1990. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed class I β-lactamases. J. Antimicrob. Chemother. 25:199-208.
2. Bennett, S., R. Wise, D. Weston, and J. Dent. 1983. Pharmacokinetics and tissue penetration of ticarcillin combined with clavulanic acid. Antimicrob. Agents Chemother. 23:831-834.
3. Blum, R. A., R. K. Kohil, N. J. Harrison, and J. J. Schentag. 1989. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob. Agents Chemother. 33:1470-1476.
4. Bush, K., C. Macalintal, B. A. Rasmussen, V. J. Lee, and Y. Yang. 1993. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob. Agents Chemother. 37:851-858.
5. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
6. Gerber, A. U., W. A. Craig, H. P. Brugger, C. Feller, A. P. Vastola, and J. Brandel. 1983. Impact of dosing interval on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J. Infect. Dis. 147:910-917.
7. Höffken, G., H. Tetzel, P. Koeppe, and H. Lode. 1986. The pharmacokinetics of ticarcillin, clavulanic acid and their combination. J. Antimicrob. Chemother. 17(Suppl. C):47-55.
8. Klepser, M. E., K. B. Patel, D. P. Nicolau, R. Quintiliani, and C. H. Nightingale. 1995. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:2503-2510.
9. Meyers, B. R., P. Wilkinson, M. H. Mendelson, S. Walsh, C. Bournazos, and S. Z. Hirschman. 1991. Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers. Antimicrob. Agents Chemother. 35:2098-2101.
10. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
11. National Committee for Clinical Laboratory Standards. 1990. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard. Publication M11-82. National Committee for Clinical Laboratory Standards, Villanova, Pa.
12. National Committee for Clinical Laboratory Standards. 1992. Methodology for the serum bactericidal test. Tentative guideline. M21-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
13. Onyeji, C. O., D. P. Nicolau, C. H. Nightingale, and R. Quintiliani. 1994. Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections. Antimicrob. Agents Chemother. 38:1112-1117.
14. Rho, J. P., A. Jones, M. Woo, S. Castle, K. Smith, R. E. Bawdon, and D. C. Norman. 1989. Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects. J. Antimicrob. Chemother. 24:573-580.
15. Sörgel, F., and M. Kinzig. 1994. Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Med. 20(Suppl. 3):S14-S20.
16. Vogelman, B., S. Gundmundsson, J. Leggett, J. Turndge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-846.
17. Wise, R., M. Logan, M. Cooper, and J. M. Andrews. 1991. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob. Agents Chemother. 35:1081-1084.